Lipoma Biopsy-XL

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Excision biopsy of fatty tumors.

₹888₹1,269

30% OFF

Lipoma Biopsy-XL: Comprehensive Medical Test Information Guide

Why is it done?
- Definitive diagnosis of lipomas and differentiation from other soft tissue masses
- Evaluation of subcutaneous nodules or masses to rule out liposarcoma or other malignancies
- Assessment of atypical or rapidly enlarging fatty tumors requiring histopathological confirmation
- Genetic and molecular analysis of lipoma tissue for research purposes or familial lipomatosis evaluation
- Performed when imaging studies (ultrasound, MRI, CT) are inconclusive or when clinical presentation warrants tissue confirmation
- Typically ordered during initial diagnosis phase or when there is concern about malignant transformation
Normal Range
- Normal/Benign Result: Histological evidence of mature adipose (fat) tissue with normal cellular architecture, absent or minimal cellular atypia, and absence of lipoblasts or malignant features
- Cellular Composition: Predominantly mature adipocytes with fibrous tissue components (normal lipoma characterized as mature, well-differentiated fat)
- Negative for Malignancy: No evidence of liposarcoma, including absence of lipoblasts, mitotic figures, or necrosis
- Molecular Findings: Normal karyotype or absence of lipoma-associated chromosomal abnormalities; may show benign lipoma characteristics (e.g., 12q13-q15 rearrangements in classical lipomas, which are non-malignant)
- Interpretation Scale: BENIGN = Normal; ATYPICAL = Requires follow-up; MALIGNANT = Positive for liposarcoma or other sarcoma
Interpretation
- Benign Lipoma (Classic Finding): Histology shows well-differentiated mature adipose tissue without cellular atypia or malignant characteristics; clinically reassuring with no need for further intervention beyond surgical excision if symptomatic; excellent prognosis
- Atypical Lipomatous Tumor (ALT)/Low-Grade Liposarcoma: Shows increased cellularity, occasional lipoblasts, and cytologic atypia; defined by specific chromosomal abnormalities (MDM2 amplification); carries risk of local recurrence and potential malignant transformation; requires close follow-up imaging and possible re-excision with wider margins
- Intermediate-Grade or High-Grade Liposarcoma: Demonstrates prominent lipoblasts, high mitotic activity, necrosis, or cellular pleomorphism; indicates malignancy with significant risk of metastasis; requires aggressive surgical management, consideration of adjuvant radiation and/or chemotherapy, and close oncological surveillance
- Inflammatory Lipoma: Shows benign lipoma with significant inflammatory infiltrate; typically benign but may be associated with symptoms; no change in malignancy risk
- Myxoid or Angiolipoma Variants: Specialized benign subtypes with distinctive histologic features; generally have excellent prognosis and low recurrence rates
- Factors Affecting Interpretation: Tumor size (larger tumors more likely to harbor malignant features), location (deeper/subfascial lipomas higher risk), patient age, rapid growth rate, imaging characteristics (MRI signal heterogeneity), and presence of cellular atypia on imaging
- Clinical Significance: Benign results are reassuring and do not require oncological treatment; atypical or malignant results necessitate aggressive management and multidisciplinary care involving surgical oncology, possibly medical oncology, and radiotherapy specialists
Associated Organs
- Primary Organ System: Integumentary system (skin and subcutaneous tissues); musculoskeletal system (superficial and deep soft tissues)
- Commonly Associated Conditions - Benign: Simple lipomas (most common benign soft tissue tumors); Dercum's disease (adiposis dolorosa); familial lipomatosis; lipomatosis of nerve (Lanois-Bensaude lipomatosis)
- Commonly Associated Conditions - Malignant: Liposarcoma (most common soft tissue sarcoma in adults); atypical lipomatous tumor; dedifferentiated liposarcoma; myxoid liposarcoma; round cell liposarcoma; pleomorphic liposarcoma
- Disorders Associated with Multiple Lipomas: Familial multiple lipomatosis (autosomal dominant); hereditary multiple exostoses with associated lipomas; metabolic syndrome-related lipomatosis
- Potential Complications of Abnormal Results: Local invasion and tissue destruction if high-grade malignancy; metastatic spread to lungs, liver, bone, and other distant organs; functional impairment if tumor involves nerves or blood vessels; increased morbidity and mortality with liposarcoma diagnosis requiring aggressive treatment
- Risk Factors for Malignancy: Tumor size >5 cm, deep subfascial location, rapid growth, older age, prior radiation exposure, Li-Fraumeni syndrome or other hereditary cancer syndromes, male gender, and specific chromosomal abnormalities (MDM2, DDIT3 amplification)
Follow-up Tests
- For Benign Lipoma Diagnosis: No imaging follow-up typically required if completely excised; clinical follow-up to monitor for recurrence or new lesions (annually or as clinically indicated); imaging only if symptomatic or if lesion does not fully resolve
- For Atypical Lipomatous Tumor/Low-Grade Liposarcoma: MRI of surgical site at 3-6 months and then every 6-12 months for 2-3 years to detect recurrence; chest imaging (CT or X-ray) to screen for pulmonary metastases; PET-CT may be considered for higher-grade lesions; surgical re-excision with wider margins often recommended
- For Intermediate to High-Grade Liposarcoma: Staging studies including CT chest, abdomen, pelvis; MRI of local site; PET-CT for metabolic activity assessment; baseline laboratory studies; oncology consultation for systemic therapy planning; post-treatment surveillance imaging at 3-month intervals for first year, then every 6 months for 2-3 years, then annually
- Additional Molecular/Genetic Testing: FISH analysis for MDM2 and DDIT3 gene amplification/translocation; cytogenetic studies for chromosomal abnormalities; immunohistochemistry for MDM2 and p16 expression; tumor gene expression profiling for prognostic information in selected cases
- Imaging Follow-up for Benign Variants: Angiolipomas and myxoid lipomas: clinical examination at 6-12 months; ultrasound if new symptoms develop; MRI only if significant growth or clinical concern arises
- Complementary Testing: Baseline CBC, comprehensive metabolic panel, and LDH for malignant cases; repeat biopsy if imaging shows concerning features despite benign initial pathology; consultation with medical oncology if systemic therapy indicated
- Monitoring Frequency: Benign: Annual clinical evaluation; ALT/Low-grade: Every 6 months clinically and with imaging; Intermediate/High-grade: Every 3 months for first 2 years, then every 6 months for years 2-5, then annually thereafter
Fasting Required?
- Fasting Requirement: NO - Fasting is not required for a lipoma biopsy procedure
- Pre-Procedure Preparation: Patient may eat and drink normally; light meal 1-2 hours prior to procedure is acceptable; maintain normal hydration unless otherwise instructed
- Medications - Discontinue Before Procedure: Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) - discontinue 3-5 days prior to biopsy; Anticoagulants (warfarin, dabigatran, apixaban, rivaroxaban) - per interventional radiologist guidelines, typically 3-5 days prior or as directed; Clopidogrel (Plavix) - discontinue 5-7 days prior if possible; contact prescribing physician for guidance
- Medications - May Continue: Most other medications including antihypertensives, diabetes medications, cardiac medications, and antidepressants; take with small sip of water on morning of procedure if needed; confirm with biopsy provider
- Pre-Procedure Laboratory Work: Coagulation studies (PT/INR, aPTT) if on anticoagulation therapy or if bleeding disorder suspected; CBC to establish baseline hemoglobin; consider bleeding time assessment if patient reports easy bruising or bleeding tendency
- Skin Preparation: Clean the area with regular soap and water on morning of biopsy; do not apply lotions, creams, or makeup to area to be biopsied; wear loose-fitting clothing to allow easy access to biopsy site
- Allergies and Medical History: Report any allergies to local anesthetic (lidocaine), antibiotics, or latex to provider; disclose history of keloid formation, bleeding disorders, or adverse anesthetic reactions; inform provider of recent infections or fever
- Transportation and Recovery: Arrange for transportation home if conscious sedation is used; a responsible adult should accompany patient if sedation is planned; plan for light activities only for 24-48 hours after procedure
- Post-Procedure Care Instructions: Keep biopsy site clean and dry; change dressing as directed; watch for signs of infection (increased redness, warmth, drainage, fever); avoid strenuous exercise or heavy lifting for 48 hours; take pain relief as needed (acetaminophen preferred over NSAIDs for 24-48 hours); report any excessive bleeding or signs of complications

How our test process works!